US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

PPBT Purple Biotech Ltd

0.36

-0.0392 (-9.82%)

15 Jul 2024 - Cerrado

Retrasado por 15 minutos

Form D - Notice of Exempt Offering of Securities

Purple Biotech (NASDAQ:PPBT)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Haga Click aquí para más Gráficas Purple Biotech.

Purple Biotech (NASDAQ:PPBT)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024

Haga Click aquí para más Gráficas Purple Biotech.

Noticias sobre Purple Biotech Ltd PPBT

Form D - Notice of Exempt Offering of Securities
Lunes 15 de Julio 2024 (4 horas hace) • Edgar (US Regulatory)

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
Miércoles 10 de Julio 2024 (6 días hace) • GlobeNewswire Inc.

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
Martes 2 de Julio 2024 (2 semanas hace) • GlobeNewswire Inc.

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
Lunes 1 de Julio 2024 (2 semanas hace) • GlobeNewswire Inc.

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
Jueves 27 de Junio 2024 (3 semanas hace) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Jueves 20 de Junio 2024 (4 semanas hace) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Martes 4 de Junio 2024 (1 mes hace) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Lunes 3 de Junio 2024 (1 mes hace) • Edgar (US Regulatory)

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
Sábado 1 de Junio 2024 (1 mes hace) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Martes 21 de Mayo 2024 (2 meses hace) • Edgar (US Regulatory)

Purple Biotech Reports First Quarter 2024 Financial Results
Martes 21 de Mayo 2024 (2 meses hace) • GlobeNewswire Inc.

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
Jueves 25 de Abril 2024 (3 meses hace) • GlobeNewswire Inc.

Más de Purple Biotech Ltd Artículos de Noticias

NLBNPIT23379 20991231 27...

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones